Literature DB >> 3481330

Pharmacokinetics of ofloxacin in patients on haemodialysis treatment.

A Dörfler1, W Schulz, F Burkhardt, M Zichner.   

Abstract

Serum concentrations and pharmacokinetic parameters of ofloxacin were measured in 10 patients on haemodialysis treatment. Serum half-life during the interdialytic interval was 48 hours, and during haemodialysis treatment 10 hours. The decrease in serum concentrations during a 4-hour haemodialysis was 25%. After several doses of ofloxacin, saturation of the tissues and a rediffusion of ofloxacin from the tissues during haemodialysis has to be assumed. This equalizes the rate of elimination, and the serum ofloxacin concentration did not change during the last 2 hours of haemodialysis. The negative influence of phosphate binders on the resorption of ofloxacin can be confirmed. The following ofloxacin dosage regimen is recommended in haemodialysis patients: 200 mg initially, 100 mg loading dose after the first haemodialysis, then 100 mg daily.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3481330     DOI: 10.2165/00003495-198700341-00014

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].

Authors:  K G Naber; D Adam; R Wittenberger; B Bartosik-Wich
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  The effect of food on the pharmacokinetics of ofloxacin.

Authors:  M Verho; V Malerczyk; E Dagrosa; A Korn
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

3.  [Ofloxacin treatment in nephrologic problem patients with various degrees of chronic renal failure (including dialysis treatment). Preliminary results].

Authors:  W Schulz; A Dörfler
Journal:  Infection       Date:  1986       Impact factor: 3.553

  3 in total
  5 in total

Review 1.  Ofloxacin clinical pharmacokinetics.

Authors:  K C Lamp; E M Bailey; M J Rybak
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 3.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 4.  Ofloxacin pharmacokinetics in chronic renal failure and dialysis.

Authors:  N Lameire; B Rosenkranz; V Malerczyk; K H Lehr; N Veys; S Ringoir
Journal:  Clin Pharmacokinet       Date:  1991-11       Impact factor: 6.447

Review 5.  Enoxacin absorption and elimination characteristics.

Authors:  R D Toothaker
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.